Yale Cancer Center | Strategic Alliance Partners

October 01, 2020

James B. Yu, MD, MHS, has been promoted to Associate Chief Medical Officer for Radiation Oncology for Smilow Cancer Hospital and Smilow Cancer Hospital Network.

September 28, 2020

Daniel P. Petrylak, MD, discusses the role of prostate-specific antigen screening in prostate cancer.

September 10, 2020

Anne Chiang, MD, PhD, discusses the management of ​immune-related adverse effects in lung cancer. 

August 12, 2020

Marianne Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, discusses the management of immune-related adverse effects in patients who are receiving treatment with checkpoint inhibitors.

July 09, 2020

In a new study by Yale Cancer Center, researchers have demonstrated that in states with expanded Medicaid coverage through the Affordable Care Act a higher percentage of women with breast cancer had their disease diagnosed at an early stage.

July 09, 2020

Markus Müschen, MD, PhD, has been named the inaugural Director of the Center of Molecular and Cellular Oncology at Yale Cancer Center and Smilow Cancer Hospital.

July 08, 2020

One of the major mysteries in treating patients with COVID-19 is the frequent development of blood clots that can subsequently damage their organs and sometimes be fatal.

July 07, 2020

Yale Cancer Center researchers were awarded a $2.8 million grant from the National Cancer Institute to evaluate and model cytokine signaling related to immunotherapy for cancer.

June 16, 2020

Roy S. Herbst MD, PhD, discusses the ADAURA trial and the impressive data seen with adjuvant osimertinib and highlights ongoing research efforts being made with the agent in lung cancer.

May 23, 2020

Lajos Pusztai, MD, DPhil, discusses the results from the I-SPY 2 trial, as well as the clinical implications of the findings.

May 22, 2020

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

May 21, 2020

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

May 01, 2020

Daniel P. Petrylak, MD, professor of medicine and urology, co-leader, Cancer Signaling Networks, Yale Cancer Center, and 2017 Giant of Cancer Care® in Genitourinary Cancers, discusses the results of the phase 1b/2 EV-103 trial in bladder cancer.

March 31, 2020

Francine Foss, MD, discusses the challenges faced in cutaneous T-cell lymphoma.

March 31, 2020

Barbara Burtness, MD, discusses the effectiveness of immunotherapy in patients with platinum-refractory head and neck cancers.

March 26, 2020

Daniel P. Petrylak, MD, discusses the current treatment landscape of metastatic urothelial carcinoma and exciting strategies in the pipeline.

March 25, 2020

Anees B. Chagpar, MD, MBA, MPH, FACS, FRCS(C), discusses the importance of taking proactive measures to prevent the spread of the novel 2019 coronavirus.

February 19, 2020

Anne Chiang, MD, PhD, discusses the currently available treatments and ongoing research in ALK-positive non–small cell lung cancer.

February 05, 2020

Roy S. Herbst, MD, PhD, discusses research regarding immunotherapy and accompanying biomarkers in non–small cell lung cancer.

January 22, 2020

Roy S. Herbst, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced non–small-cell lung cancer (NSCLC).